ALMS
Price
$26.34
Change
-$0.70 (-2.59%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
3.37B
49 days until earnings call
Intraday BUY SELL Signals
ZBIO
Price
$20.63
Change
+$0.91 (+4.61%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
1.06B
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALMS vs ZBIO

Header iconALMS vs ZBIO Comparison
Open Charts ALMS vs ZBIOBanner chart's image
Alumis
Price$26.34
Change-$0.70 (-2.59%)
Volume$18.68K
Capitalization3.37B
Zenas Biopharma
Price$20.63
Change+$0.91 (+4.61%)
Volume$12.02K
Capitalization1.06B
ALMS vs ZBIO Comparison Chart in %
ALMS
Daily Signal:
Gain/Loss:
ZBIO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ALMS vs. ZBIO commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALMS is a Buy and ZBIO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ALMS: $27.04 vs. ZBIO: $19.72)
Brand notoriety: ALMS and ZBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALMS: 25% vs. ZBIO: 79%
Market capitalization -- ALMS: $3.37B vs. ZBIO: $1.06B
ALMS [@Biotechnology] is valued at $3.37B. ZBIO’s [@Biotechnology] market capitalization is $1.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALMS’s FA Score shows that 1 FA rating(s) are green whileZBIO’s FA Score has 0 green FA rating(s).

  • ALMS’s FA Score: 1 green, 4 red.
  • ZBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, ALMS is a better buy in the long-term than ZBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALMS’s TA Score shows that 3 TA indicator(s) are bullish while ZBIO’s TA Score has 5 bullish TA indicator(s).

  • ALMS’s TA Score: 3 bullish, 5 bearish.
  • ZBIO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ZBIO is a better buy in the short-term than ALMS.

Price Growth

ALMS (@Biotechnology) experienced а +4.00% price change this week, while ZBIO (@Biotechnology) price change was -1.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.56%. For the same industry, the average monthly price growth was +1.40%, and the average quarterly price growth was +33.10%.

Reported Earning Dates

ALMS is expected to report earnings on Mar 25, 2026.

ZBIO is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (-2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALMS($3.37B) has a higher market cap than ZBIO($1.06B). ZBIO has higher P/E ratio than ALMS: ZBIO (1.44) vs ALMS (0.17). ALMS YTD gains are higher at: 177.049 vs. ZBIO (-45.690). ZBIO has higher annual earnings (EBITDA): -195.62M vs. ALMS (-452.53M). ALMS has more cash in the bank: 378M vs. ZBIO (291M). ZBIO has less debt than ALMS: ZBIO (798K) vs ALMS (37.8M). ALMS has higher revenues than ZBIO: ALMS (22.1M) vs ZBIO (15M).
ALMSZBIOALMS / ZBIO
Capitalization3.37B1.06B319%
EBITDA-452.53M-195.62M231%
Gain YTD177.049-45.690-388%
P/E Ratio0.171.4412%
Revenue22.1M15M147%
Total Cash378M291M130%
Total Debt37.8M798K4,737%
FUNDAMENTALS RATINGS
ZBIO: Fundamental Ratings
ZBIO
OUTLOOK RATING
1..100
59
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
92
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ALMSZBIO
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 8 days ago
90%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ALMS
Daily Signal:
Gain/Loss:
ZBIO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SMSAX10.250.09
+0.89%
SEI Multi Strategy Alternatives F (SIMT)
RYDVX2.400.01
+0.42%
Royce Smid-Cap Total Return Service
MCLVX29.220.07
+0.24%
BlackRock Advantage Large Cap Val Inv C
LMPMX35.87-0.14
-0.39%
ClearBridge Small Cap Growth 1
OGLNX81.33-2.29
-2.74%
Invesco Global R

ALMS and

Correlation & Price change

A.I.dvisor tells us that ALMS and KRRO have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALMS and KRRO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALMS
1D Price
Change %
ALMS100%
+2.35%
KRRO - ALMS
26%
Poorly correlated
-2.68%
ZNTL - ALMS
24%
Poorly correlated
+12.35%
ZBIO - ALMS
24%
Poorly correlated
+8.65%
INCY - ALMS
23%
Poorly correlated
-1.70%
GERN - ALMS
22%
Poorly correlated
-1.95%
More

ZBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZBIO has been loosely correlated with RGNX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBIO jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZBIO
1D Price
Change %
ZBIO100%
+8.65%
RGNX - ZBIO
44%
Loosely correlated
+0.74%
PYXS - ZBIO
43%
Loosely correlated
-2.61%
SYRE - ZBIO
42%
Loosely correlated
+1.65%
XENE - ZBIO
42%
Loosely correlated
+1.62%
REPL - ZBIO
41%
Loosely correlated
+5.81%
More